A. Rezvan

Metabolic plasticity of T-cell therapies: multi-omic profiling of interacting human tumor-infiltrating lymphocytes and autologous tumor adoptive cell therapy

This study profiles the metabolic interactions between TILs and autologous tumor cells in ACT, finding that responder TILs are more efficient at fatty acid oxidation under starvation.

Engineering non-cytotoxic delivery of proteins by T cells via fusion to NPC2

This study demonstrates that fusing proteins to NPC2 enables non-cytotoxic protein delivery by T cells through the perforin pathway.

Integrated single-cell functional and molecular profiling of extracellular vesicle secretion in metastatic breast cancer

The paper identifies a four-gene signature associated with EV secretion in breast cancer and links it to poor prognosis and immune evasion.

Ending transmission of SARS-CoV-2: sterilizing immunity using an intranasal subunit vaccine

This paper develops an intranasal multi-antigen vaccine that prevents SARS-CoV-2 infection and transmission by targeting both spike and nucleocapsid proteins.

T-cell potential for CD19-expressing malignancies revealed by multi-dimensional single-cell profiling

The paper identifies migration as a cell-intrinsic biomarker for CAR+ T cell efficacy in B-cell malignancies using multi-dimensional single-cell profiling.

Multidimensional single-cell analysis identifies a role of CD2-CD58 interactions for clinical antitumor T cell responses

This study identifies CD2-CD58 interactions as critical for CAR T cell persistence and antitumor responses in lymphoma patients.

Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2

This study develops an intranasal vaccine that induces systemic and mucosal immunity against SARS-CoV-2 in mice, with single-cell RNA-sequencing confirming T and B cell responses in nasal-associated lymphoid tissues.

CIS checkpoint deletion enhances the fitness of cord blood derived natural killer cells transduced with a chimeric antigen receptor

This paper combines CIS checkpoint deletion with CAR engineering in NK cells to enhance their metabolic fitness and anti-tumor activity in a lymphoma model.